Leaders of Gritstone Bio Inc. could read the writing on the wall: Financial times for drug developers are tough and the ...

Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...

In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...

This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...

In June, we heard what could be this year's biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works.

Lenacapavir is a long-acting injectable drug that has proven 100 per cent successful in clinical tests and subsequent human ...

Since its inception in 1992, the FDA’s accelerated approval pathway has helped shepherd nearly 300 new drugs to the market.

(医药健闻2024年10月12日讯)Hetero宣布与Gilead ...

GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted ...

Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target ...

The growing occurrence of pediatric conditions like HIV, cancer, diabetes, and others is boosting the need for treatments specifically designed for children, making pediatric drug development ...